Zdroje:
1. [1] Patent protected in China (ZL 201310628174.8), Hong Kong (1210838), and the United States (10268050 & 11029540).
2. The Hong Kong Polytechnic University. QS World University Rankings. 2023. Available from: https://www.topuniversities.com/universities/ivanovo (Last accessed: 28/06/2023).
3. Six PolyU researchers ranked in the Top 200 in optometry. The Hong Kong Polytechnic University. April 2021. Available from: https://www.polyu.edu.hk/publications/pulse-polyu/issue/202104/achievements/six-polyu-researchers-ranked-in-the-top-200-in-optometry (Last accessed: 28/06/2023).
4. Lam CS, Tang WC, Tse DY, Tang YY, To CH. Defocus Incorporated Soft Contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol. 2014;98(1):40-5. doi:10.1136/bjophthalmol-2013-303914.
5. Berntsen DA, Barr CD, Mutti DO, Zadnik K. Peripheral defocus and myopia progression in myopic children randomly assigned to wear single vision and progressive addition lenses. Invest Ophthalmol Vis Sci. 2013;54(8):5761-70. doi:10.1167/iovs.13-11904.
6. Németh J, Tapasztó B, Aclimandos WA, et al. Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute. Eur J Ophthalmol. 2021;31(3):853-883. doi:10.1177/1120672121998960.
7. Troilo D, Smith EL 3rd, Nickla DL, et al. IMI – Report on Experimental Models of Emmetropization and Myopia. Invest Ophthalmol Vis Sci. 2019;60(3):M31-M88. doi:10.1167/iovs.18-25967.
8. IMI White Papers & Clinical Summaries. International Myopia Institute. 2023. Available from: https://myopiainstitute.org/imi-white-papers/ (Last accessed: 28/06/2023).
9. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368. doi:10.1136/bjophthalmol-2018-313739.
10. Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol. 2022;106(8):1110-1114. doi:10.1136/bjophthalmol-2020-317664.
11. Lam CSY, Tang WC, Zhang HY, Lee PH, Tse DYY, Qi H, Vlasak N, To CH. Long-term myopia control effect and safety in children wearing DIMS spectacle lenses for 6 years. Sci Rep. 2023 Apr 4;13(1):5475.
12. McCullough S, Barr H, Fulton J, et al. 2-Year Multi-Site Observational Study of MiYOSMART myopia control spectacle lenses in UK children:1-year results (Abstract). ARVO 2023. 23-27 April 2023. New Orleans, LA, USA.
-
Liu L, Li X. Myopia progression and visual performance of Chinese children wearing Defocus Incorporated Multiple Segments Spectacle Lens (DIMS) (Abstract). ARVO 2023 23-27 April 2023. New Orleans, LA, USA.
14. Lu Y, Lin Z, Wen L, et al. The Adaptation and Acceptance of Defocus Incorporated Multiple Segment Lens for Chinese Children. Am J Ophthalmol. 2020;211:207-216. doi:10.1016/j.ajo.2019.12.002.
15. Jaskulski M, Singh NK, Bradley A, Kollbaum PS. Optical and imaging properties of a novel multi-segment spectacle lens designed to slow myopia progression. Ophthalmic Physiol Opt. 2020;40(5):549-556. doi:10.1111/opo.12725.
16. Kaymak H, Neller K, Schütz S, et al. Vision tests on spectacle lenses and contact lenses for optical myopia correction: a pilot study. BMJ Open Ophthalmol. 2022;7(1):e000971. Published 2022 Apr 5. doi:10.1136/bmjophth-2022-000971.
17. Kaymak H, Mattern AI, Graff B, et al. Safety of DIMS Spectacle Lenses and Atropine as Combination Therapy for Myopia Progression. Sicherheit von Brillengläsern mit DIMS-Technologie und Atropin in der Kombinationstherapie der Myopieprogression. Klin Monbl Augenheilkd. 2022;239(10):1197-1205. doi:10.1055/a-1930-7116.
18. Kaymak H. Controlling the growing problem of myopia in children. November 2022. Available from: https://europe.ophthalmologytimes.com/view/controlling-the-growing-problem-of-myopia-in-children (Last accessed: 28/06/2023).
19. Huang Z, Chen XF, He T, Tang Y, Du CX. Synergistic effects of defocus-incorporated multiple segments and atropine in slowing the progression of myopia. Sci Rep. 2022 Dec 24;12(1):22311. doi: 10.1038/s41598-022-25599-z. Erratum in: Sci Rep. 2023 Jun 14;13(1):9650.
20. Nucci P, Lembo A, Schiavetti I, Shah R, Edgar DF, Evans BJW. A comparison of myopia control in European children and adolescents with defocus incorporated multiple segments (DIMS) spectacles, atropine, and combined DIMS/atropine. PLoS One. 2023 Feb 16;18(2):e0281816. doi: 10.1371/journal.pone.0281816.
21. Brennan NA, Toubouti YM, Cheng X, Bullimore MA. Efficacy in myopia control. Prog Retin Eye Res. 2021;83:100923. doi:10.1016/j.preteyeres.2020.100923.
22. Kaymak, H., Graff, B., Neller, K. et al. Myopia treatment and prophylaxis with defocus incorporated multiple segments spectacle lenses [German]. Ophthalmologe. 2021;118:1280-1286. doi: 10.1007/s00347-021-01452-y.
23. WSPOS. Myopia Consensus Statement 2023. 2023. Available from: https://www.wspos.org/swdcore/uploads/WSPOS-Myopia-Consensus-Statement-2023-1.pdf (Last accessed: 28/06/2023).
24. Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 Yearly Digest. Invest Ophthalmol Vis Sci. 2021;62(5):7. doi: 10.1167/iovs.62.5.7.
25. Based on number of MiYOSMART lenses sold per Hoya sales data on file as of December 2022.